Novel Antibody May Reduce Amyloid, Cut AD Symptoms

Lecanemab can reduce amyloid plaques within the first months after treatment initiation and is linked to improved clinical signs in as early as 6 months, updates from a phase 2 trial show.

Related Keywords

United States ,American ,Fernando Testai ,American Academy Of Neurology ,Eisai Pharmaceuticals ,University Of Illinois At Chicago ,Chad Swanson ,American Academy ,Amyloid Plaques ,Key Driver ,Best Dose ,Dose Frequency ,Alzheimers Disease ,Lzheimer Disease ,Biomarker ,Iological Marker ,Positron Emission Tomography Pet ,Pet ,Positron Emission Tomography ,Blindness ,Cognitive Impairment ,Mci ,Mild Cognitive Impairment ,